Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-01-01
2008-01-01
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C424S141100, C424S135100, C424S142100, C424S174100, C424S192100, C530S350000, C530S387100, C530S387300, C530S387900, C530S388150, C530S388220, C530S388800, C514S002600
Reexamination Certificate
active
10052798
ABSTRACT:
Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4342566 (1982-08-01), Theofilopoulos et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4496689 (1985-01-01), Mitra
patent: 4601978 (1986-07-01), Karin
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4855235 (1989-08-01), Takahashi et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 4965199 (1990-10-01), Capon et al.
patent: 5010182 (1991-04-01), Brake et al.
patent: 5153118 (1992-10-01), Wright, Jr. et al.
patent: 5158885 (1992-10-01), Bradstock et al.
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5910574 (1999-06-01), Presta et al.
patent: 6046048 (2000-04-01), Ashkenazi et al.
patent: 6072047 (2000-06-01), Rauch et al.
patent: 6252050 (2001-06-01), Ashkenazi et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6342369 (2002-01-01), Ashkenazi
patent: 6417328 (2002-07-01), Alnemri
patent: 6455040 (2002-09-01), Wei et al.
patent: 6455262 (2002-09-01), Cox et al.
patent: 6635743 (2003-10-01), Ebner et al.
patent: 6689744 (2004-02-01), Gao et al.
patent: 6743625 (2004-06-01), Ni et al.
patent: 6872568 (2005-03-01), Ni
patent: 2002/0048566 (2002-04-01), El-Deiry et al.
patent: 2002/0048785 (2002-04-01), Holtzman
patent: 2002/0072091 (2002-06-01), Ni et al.
patent: 2002/0098550 (2002-07-01), Ni et al.
patent: 2002/0115154 (2002-08-01), Alnemri
patent: 2002/0150985 (2002-10-01), Adams
patent: 2002/0160446 (2002-10-01), Holtzman
patent: 2002/0161195 (2002-10-01), Alnemri
patent: 2002/0161196 (2002-10-01), Alnemri
patent: 2003/0004313 (2003-01-01), Ashkenazi
patent: 2003/0017161 (2003-01-01), Ashkenazi
patent: 2003/0133932 (2003-07-01), Zhou et al.
patent: 2003/0148455 (2003-08-01), Ashkenazi
patent: 2003/0180296 (2003-09-01), Salcedo et al.
patent: 2004/0009552 (2004-01-01), Adams
patent: 2004/0136951 (2004-07-01), Ni et al.
patent: 2005/0233958 (2005-10-01), Ni
patent: 2005/0282230 (2005-12-01), Ashkenazi
patent: 2006/0035334 (2006-02-01), Adams
patent: 2006/0073570 (2006-04-01), Adams
patent: 2006/0084147 (2006-04-01), Adams
patent: 266710 (1989-04-01), None
patent: 036776 (1981-09-01), None
patent: 073657 (1983-03-01), None
patent: 117058 (1984-08-01), None
patent: 117060 (1984-08-01), None
patent: 125023 (1984-11-01), None
patent: 173494 (1986-03-01), None
patent: 278776 (1988-08-01), None
patent: 307247 (1989-03-01), None
patent: 321196 (1989-06-01), None
patent: 362179 (1990-04-01), None
patent: 417563 (1991-03-01), None
patent: 510691 (1992-10-01), None
patent: 870827 (1998-10-01), None
patent: 870827 (1998-10-01), None
patent: 2211504 (1989-07-01), None
patent: WO 87/05330 (1987-09-01), None
patent: WO 89/02922 (1989-04-01), None
patent: WO 89/05859 (1989-06-01), None
patent: WO 90/13646 (1990-11-01), None
patent: 91/00360 (1991-01-01), None
patent: WO 91/00358 (1991-01-01), None
patent: WO 91/08291 (1991-06-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/01810 (1992-02-01), None
patent: 92/20373 (1992-11-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: 93/08829 (1993-05-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 93/19172 (1993-09-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/04690 (1994-03-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 95/01438 (1995-01-01), None
patent: WO 95/10540 (1995-04-01), None
patent: WO 95/11301 (1995-04-01), None
patent: WO 95/15388 (1995-06-01), None
patent: WO 95/31544 (1995-11-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 98/35986 (1998-08-01), None
patent: WO 98/41629 (1998-09-01), None
patent: WO 98/46643 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 98/58062 (1998-12-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/09165 (1999-02-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12963 (1999-03-01), None
patent: WO 99/64461 (1999-12-01), None
patent: WO 00/66156 (2000-11-01), None
patent: WO 00/77191 (2000-12-01), None
patent: WO 02/053727 (2002-07-01), None
patent: WO 02/094880 (2002-11-01), None
patent: WO 03/037913 (2003-05-01), None
patent: WO 03/038043 (2003-05-01), None
U.S. Appl. No. 08/815,255, filed Mar. 12, 1997.
U.S. Appl. No. 08/829,536, filed Mar. 28, 1997.
U.S. Appl. No. 08/883,036, filed Jun. 26, 1997.
Adams et al., “Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for μ, α, γ1, γ2a, and γ3 chains”Biochemistry19:2711-2719 (1980).
Amakawa et al., “The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells”Symposium on Programmed Cell Death(Abstract No. 10), Cold Spring Harbor Laboratory (1995).
Aplin and Wriston, “Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids”CRC Crit. Rev. Biochem. 10 (4) :259-306 (1981).
Ashkenazi and Chamow, “Immunoadhesins: An Alternative to Human Monoclonal Antibodies”Methods: A Companion to Methods in Enzymology8:104-115 (1995).
Ashkenazi et al., “Induction of Apoptosis by APO-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family”European Cytokine Network7:159 (1996).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”Proc. Natl. Acad. Sci. 88:10535-10539 (1991).
Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium, Dicke et al., University of Texas M.D. Anderson Hospital (1987).
Baldwin, A., “The NF-κB and IκB Proteins: New Discoveries and Insights”Ann. Rev. Immunol. 14:649-683 (1996).
Banerji et al., “A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes”Cell33:729-740 (Jul. 1983).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”Cell73:431-445 (1993).
Barr and Tomei, “Apoptosis and Its Role in Human Disease”Bio/Technology12:487-493 (1994).
Bianchi et al., “Transformation of the yeastKluyveromyces lactisby New Vectors Derived from the 1.6 μm Circular Plasmid pKD1”Curr. Genet. 12:185-192 (1987).
“BLAST Results A-1-A-47” (GenBank).
“BLAST Results B-1-B-31” (GenBank, -EST).
“BLAST Results C-1-C-36” (Patent).
“BLAST Results D-1-D-40” (Dayhoff-patent).
“BLAST Results E-1-E-25” (Human -pat).
“BLAST Results F-1-F-52” (Dayhoff).
Bodmer et al., “TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas (Apo-1/CD95)”Immunity6:79-88 (1997).
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes”The Journal of Immunology147 (1) : 86-95 (1991).
Boldin et al., “Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death”Cell85:803-815 (1996).
Boldin et al., “Self-Association of the “Death Domains” o
Adams Camellia W.
Ashkenazi Avi J.
Chuntharapai Anan
Kim Kyung Jin
Genentech Inc.
Marschang Diane L.
O'Hara Eileen B.
Sidley Austin LLP
LandOfFree
Inducing apoptosis using anti-Apo-2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inducing apoptosis using anti-Apo-2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inducing apoptosis using anti-Apo-2 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3904587